RALEIGH, N.C. and OCEAN SPRINGS, Miss., June 2, 2011 (GLOBE NEWSWIRE) -- InoLife Technologies, Inc. (OTCBB:INOL), an innovative healthcare products development and marketing company has announced the first delivery of its highly competitive DNA-based products to Gulf Coast Pharmaceuticals, Inc. for distribution and sales nationwide. The delivery included over $300,000 of the company's signature DNA-based products. Gulf Coast is a pharmaceutical supply company specializing in the nationwide distribution of pharmaceuticals and medical supplies to the healthcare industry.
"This initial delivery of our products is the first of what we project to be many, under our Agreement with Gulf Coast. Gulf Coast will sell our products to its current base of consumers, hospitals, general practitioners and cardiologists," said Gary Berthold, CEO of InoLife. "We believe our Genetic Predisposition Test is superior to those in the marketplace and we expect it will continue to receive broad acceptance as Gulf Coast markets this first delivery of inventory for re-sale This DNA test reveals genetic predispositions for 25 diseases and conditions in five major categories. Gulf Coast will also distribute InoLife's Cytochrome CYP2C19drug metabolism analysis, a test that determines if a patient has a genetic variation that may reduce the effectiveness of Plavix. If that patient has the genetic variation, the risk of having a stroke, heart attack or other serious cardiac event is higher.
About InoLife Technologies, Inc.
InoLife Technologies, Inc. is a leader in the development and marketing of state-of-the-art DNA Testing products within the US. The Company's mission is to aggressively identify, develop and deliver innovative and affordable healthcare products and services directly to the marketplace. By targeting cutting-edge DNA-based testing and reporting methodologies, the Company is able to significantly benefit the health and wellness needs of both individuals and their healthcare providers.
InoLife Technologies, Inc. has developed a range of products that will be sold directly to consumers through e-commerce, direct sales, pharmacies, retailers, distributors and healthcare providers. It also offers products that are sold only to physicians, hospitals, outpatient facilities and others in the medical community for use with their patients.
About Gulf Coast Pharmaceuticals, Inc. Gulf Coast Pharmaceuticals is a full line pharmaceutical supply company that specializes in the nationwide distribution of pharmaceuticals and medical supplies to the healthcare industry. Based in Ocean Springs, Mississippi, we currently distribute pharmaceuticals to hospitals, physician's offices, and other wholesalers both domestic and international.
Safe Harbor Statement under the Private securities Litigation Reform Act of 1995: The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements including, but not limited to, certain delays beyond the Company's control with respect to market acceptance of new technologies, products and services, delays in testing and evaluation of products and services, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.
CONTACT: INVESTOR RELATIONS: Steve Reiss BUZZBAHN, LLC 516-570-3850 firstname.lastname@example.org www.buzzbahnllc.com